This statement summarises the available evidence regarding how contraception may affect a woman’s weight and how a woman’s weight may affect contraceptive efficacy. Looking at each method individually, the CEU advises clinicians on what proven and theoretical associations exist between contraception and weight.
Filter documents Clear search
CEU Statement: Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants - March 2017
This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.
Change of UKMEC category for use of progestogen-only injectable contraception by women at high risk of HIV infection from UKMEC1 to UKMEC2
A short documentary hosted on the Guardian website highlights some fatal cases of venous thrombosis that were associated with use of combined hormonal contraception.
A recently published multinational trial reports no pregnancies among 311 women who extended use of their existing Nexplanon® to four years and 204 women who continued to five years of use.[
This statement is a CEU response to a study published in JAMA Psychiatry titled Association of Hormonal Contraception with Depression.
Updated Document - Please note, this document was updated in September 2016. The previous version was published in August 2016.
CEU Statement: Contraception advice for individuals travelling to Brazil for the 2016 Olympics and their partners (revised 28 July 2016)
After reviewing the available body of evidence, the Centers for Disease Control (CDC) in the USA have concluded that a causal relationship exists between prenatal Zika virus infection and microcephaly and other serious brain anomalies. Cases of locally-transmitted Zika virus are still being reported in Brazil and most of its neighbouring countries.
This statement is a CEU response to a study published in the BMJ titled Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD to healthcare professionals in the UK regarding a small number of reports of Nexplanon contraceptive implants inadvertently inserted into blood vessels.